APR 23, 2020 11:39 AM PDT

Dual Inhibition from One Chemotherapy

WRITTEN BY: Jasper Cantrell

Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary chemotherapeutic targets are usually receptor tyrosine kinases. One such kinase is called FLT3. FLT3 is a receptor tyrosine kinase that initiates several downstream pathways involved in cellular proliferation, including Akt, mTOR, and several others. Specific mutations called internal tandem repeats, or FLT3-ITD, cause uncontrolled activation of FLT3 and its downstream pathways. This uncontrolled activation quickly leads to cancer transformation. While several inhibitors exist for FLT3, they all suffer from minor complications, and cancers treated with them were prone to generate resistance against them.

A group from the United Kingdom began an investigation into a new dual inhibitor, CCT241736, that seemed to overcome the issues seen in other FLT3 inhibitors. This new compound had been shown previously to bind to both FLT3, and another kinase called aurora kinase. The aurora kinase is involved in mitosis, and inhibition can result in cell cycle arrest, which can induce cell death. They began their testing by measuring CCT241736 against other aurora kinase inhibitors on AML cell lines in vitro. Standard inhibitors exhibited mixed results, where CCT241736 produced proper cell cycle arrest that induced cell death. This result proved its efficacy in selective inhibition of aurora kinase over other inhibitors.

Next, they decided to examine CCT241736s FLT3 inhibitory abilities. It was shown in previous work that the resistance developed by cancer cells was due to secondary mutations on top of the original ITD. Testing CCT241736 on a screen of FLT3 inhibitor-resistant AML cell lines revealed that CCT241736 was tens of times more potent in its suppression of growth when compared to other FLT3 inhibitors. Mouse experiments confirmed this, and no resistance developed against CCT241736 even after 107 days of treatment. This data suggests that CCT241736 uniquely interacts with FLT3 that, that prevents resistance by new mutations seen in other inhibitors.

The dual inhibitory capabilities of CCT241736 FLT3 and aurora kinase make it a great candidate for possible chemotherapy. Its oral bioavailability and low blood clearance are big pluses in actual treatment as well. The actual mechanism by which CCT241736 inhibits both FLT3 and aurora kinase still needs to be investigated. However, the results of this paper make CFT241736 an attractive target for future chemotherapy research.

Sources: Blood Advances, OncLiveTV
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 04, 2020
Cancer
APR 04, 2020
Unique Cancer Mutation Hijacks Nearby Signaling Pathway
  In cancer, tyrosine kinase mutations are quite common. MET is one such example that normally binds its native lig ...
MAR 31, 2020
Cancer
MAR 31, 2020
Ovarian cancer metastasis and CPT1A
Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado C ...
APR 23, 2020
Cancer
APR 23, 2020
Doctors, watch out for unexpected side effects in small clinical trials
Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpe ...
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Drug Targets Hard To Treat Uterine Cancer
A clinical trial was deemed successful when evaluating a therapeutic for a hard-to-treat form of uterine cancer. The dru ...
MAY 09, 2020
Cancer
MAY 09, 2020
Disney movies boost quality of life during chemo
Have you considered popping in a Disney movie during your next chemotherapy session? A study published recently in JAMA ...
MAY 17, 2020
Cancer
MAY 17, 2020
Text message reminders don't cut it
New research published in the Journal of Clinical Oncology shows that contrary to previous investigations’ results ...
Loading Comments...